Allergan CEO Saunders warms up to drug discovery

By Ransdell Pierson and Bill Berkrot NEW YORK (Reuters) - Brenton Saunders, the whiz-kid pharmaceutical executive with a reputation for being wary of the costs of early-stage drug development, says he's open to new ideas from outside and is now warming up to investing in drug discovery if it makes sense for his company. "I practice a very open minded management structure and learn new things all the time that change my opinion," Saunders, 45, said in a phone interview with Reuters from an Allerg